Maintenance Dovitinib for Colorectal and Pancreas Cancer
Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is for patients with stage 4 colon cancer who have had initial chemotherapy or had
surgery to remove metastases and patients with pancreas cancer, which has been surgically
removed and are receiving adjuvant chemotherapy or is locally advanced and have already
received chemotherapy and radiation.
The purpose of this study is to determine the effects of oral dovitinib in patients with
advanced stage colorectal and pancreas. Effects include biomarker changes, progression-free
survival and safety. Dovitinib will be taken by mouth for 5 days out of every week for up to
2 years.